Related Experiment Video
Updated: Jul 4, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Overcoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers
Wesam R Kadhum1, Ali A Majeed2, Raed Obaid Saleh3
1Department of Pharmacy, Kut University College, Kut 52001, Wasit, Iraq; Advanced research center, Kut University College, Kut 52001, Wasit, Iraq.
Abstract:
Metastatic cancer, which accounts for the majority of cancer fatalities, is a difficult illness to treat. Currently used cancer treatments include radiation therapy, chemotherapy, surgery, and targeted treatment (immune, gene, and hormonal). The disadvantages of these treatments include a high risk of tumor recurrence and surgical complications that may result in permanent deformities. On the other hand, most chemotherapy drugs are small molecules, which usually have unfavorable side effects, low absorption, poor selectivity, and multi-drug resistance. Anticancer drugs can be delivered precisely to the cancer spot by encapsulating them to reduce side effects. Stimuli-responsive nanocarriers can be used for drug release at cancer sites and provide target-specific delivery. As previously stated, metastasis is the primary cause of cancer-related mortality. We have evaluated the usage of nano-medications in the treatment of some metastatic tumors.
Insights
This study explores nano-medications for treating metastatic cancer, aiming to improve drug delivery and reduce side effects associated with traditional therapies like chemotherapy.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Metastatic cancer is a leading cause of cancer mortality, posing significant treatment challenges.
- Current therapies (chemotherapy, radiation, surgery) have limitations including recurrence, side effects, and poor drug selectivity.
- Nanocarriers offer a promising approach for targeted drug delivery to cancer sites, potentially overcoming these limitations.
Purpose of the Study:
- To evaluate the efficacy of nano-medications in treating metastatic tumors.
- To explore the potential of stimuli-responsive nanocarriers for targeted anticancer drug release.
- To address the limitations of conventional cancer treatments through advanced drug delivery systems.
Main Methods:
- Encapsulation of anticancer drugs into nanocarriers for precise delivery.
- Utilizing stimuli-responsive nanocarriers for controlled drug release at tumor sites.
- Investigating the application of nano-medications in preclinical models of metastatic cancer.
Main Results:
- Nano-encapsulation enhances drug delivery precision to cancer cells.
- Stimuli-responsive nanocarriers facilitate targeted drug release, minimizing systemic exposure.
- Preliminary evaluations suggest potential benefits of nano-medications in managing metastatic tumors.
Conclusions:
- Nano-medications represent a viable strategy to improve the treatment of metastatic cancer.
- Targeted drug delivery via nanocarriers can mitigate side effects and enhance therapeutic outcomes.
- Further research into stimuli-responsive nanocarriers is warranted for advanced cancer therapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy